MAPK10-AS1: A Potential Drug Target and Biomarker (G101929064)

Target Name: MAPK10-AS1

NCBI ID: G101929064

MAPK10-AS1

Other Name(s): MAPK10 antisense RNA 1

MAPK10-AS1: A Potential Drug Target and Biomarker

MAPK10-AS1, also known as MAPK10-AS1 RNA, is a non-coding RNA molecule that has been identified as a potential drug target and biomarker.MAPK10-AS1 is a key regulator of the mitochondrial dynamics, and its levels have been linked to a range of cellular processes, including cell growth, apoptosis, and inflammation.

MAPK10-AS1 is a member of the MAPK10 family of RNA molecules, which are involved in the regulation of mitochondrial function. The MAPK10 family includes several different isoforms, including MAPK10-AS1, which are involved in the regulation of mitochondrial dynamics and the dynamics of cellular processes that require the services of the mitochondria.

MAPK10-AS1 is expressed in a variety of tissues and cells, including skeletal muscles, heart cells, and immune cells. It has been shown to play a role in the regulation of mitochondrial dynamics, including the mitochondrial fission that occurs during muscle contraction.

MAPK10-AS1 has also been shown to be involved in the regulation of cellular processes that require the services of the mitochondria, including cell growth, apoptosis, and inflammation. For example, studies have shown that MAPK10-AS1 plays a role in the regulation of cell growth and apoptosis, and that its levels are involved in the development of cancer.

In addition to its role in the regulation of mitochondrial dynamics, MAPK10-AS1 has also been shown to be involved in the regulation of cellular interactions. For example, studies have shown that MAPK10-AS1 is involved in the regulation of the interactions between cells and extracellular matrix (ECM) components, including ECM proteins and ECM-derived signaling molecules.

Given its involvement in a range of cellular processes, MAPK10-AS1 has potential as a drug target. Studies have shown that inhibiting the activity of MAPK10-AS1 can have a range of cellular effects, including the inhibition of cell growth, apoptosis, and inflammation.

In addition to its potential as a drug target, MAPK10-AS1 has also been identified as a potential biomarker. Studies have shown that the levels of MAPK10-AS1 are involved in the regulation of cellular processes that are associated with the development of a range of diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

Given its potential as a drug target and biomarker, MAPK10-AS1 is an interesting target for further research. Further studies are needed to fully understand its role in cellular processes and its potential as a drug and biomarker. Additionally, research is needed to determine the most effective and efficient method for its inhibition.

In conclusion, MAPK10-AS1 is a non-coding RNA molecule that has been shown to play a role in the regulation of mitochondrial dynamics and cellular processes. Its levels are involved in the regulation of cell growth, apoptosis, and inflammation, and it has potential as a drug target and biomarker. Further research is needed to fully understand its role in cellular processes and its potential as a drug and biomarker.

Protein Name: MAPK10 Antisense RNA 1

The "MAPK10-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MAPK10-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets